1.460USD-14.12%Mkt Cap: 26.01M USDP/E: —Last update: 2026-05-29
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap26.01M USD
Enterprise Value4.05M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.47M USD
Revenue/Share—
Last Price1.460 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.92
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.43
EPS (TTM)-0.80
EPS (Forward)-0.71
52W Range
0.489057% of range2.200
52W High2.200 USD
52W Low0.4890 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-202.73%
ROA-164.00%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.80M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-21.31%
Net Debt-6.24M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio4.72
Quick Ratio4.30
Book Value/Sh0.3960 USD
Cash/Share0.3840 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateOct 26, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.19.13M
Float15.79M
Insiders2.89%
Institutions4.11%
Short Interest
Short Ratio0.1d
Short % Float4.29%
Short % Out.4.17%
Shares Short797.31K
Short (prev mo.)749.81K
Technical
SMA 500.7462 (+95.6%)
SMA 2001.112 (+31.3%)
Beta0.58
S&P 52W Chg27.94%
Avg Vol (30d)8.58M
Avg Vol (10d)27.05M
Technical Indicators
RSI (14)88.8
MACD0.1004
MACD Signal0.0058
MACD Hist.+0.0946
BB Upper1.282 USD
BB Middle0.7550 USD
BB Lower0.2282 USD
BB Width139.55%
ATR (14)0.1668 USD
Vol Ratio (20d)13.06x